Sonendo, Inc. · OTC:SONX
Sonendo — Investor Presentation (August 2025)
24 slides from Sonendo's investor presentation, Aug 13, 2025
Slide 1: Corporate Presentation
Corporate Presentation August 13, 2025
Slide 2: Disclaimer Notice
Disclaimer Notice This presentation contains forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to
Slide 3: Our Mission: Saving Teeth. Restoring Health.
OUR MISSION Saving Teeth. Restoring Health. WHAT THIS MEANS Establish the GentleWave® Procedure as the standard of care for tooth decay, with an initial focus on transforming root canal therapy.
Slide 4: Sonendo Management Team
Sonendo Management Team Bjarne Bergheim John Bostjancic John McGaugh Kevin Yein Bob Guyatt President & CEO CFO SVP, Operations VP, R&D SVP, Marketing 4
Slide 5: The Sonendo Opportunity
The Sonendo Opportunity Creating a Market Leader in Root Canal Therapy (RCT) Attractive $1.9B US & Canada Market: Opportunity to expand market opportunity by going International and beyond root canal therapy Proven Technology: GentleWave System shown to be highly efficacious, safe, and reliable in R
Slide 6: The Sonendo Opportunity
The Sonendo Opportunity Recurring Revenue Model with High Margin Consumables Paradigm Shifting Platform Technology for Tooth Decay: Proven Technology with GentleWave System® Compelling Body of Clinical Evidence Initial Focus on Root Canal Therapy (RCT) 1.7mm+ Procedures and >650 Active User Base2 Op
Slide 7: Large Market for Root Canal Therapy (RCT)
Large Market for Root Canal Therapy (RCT) Large Recurring US & Canada RCT Procedure Volumes (~17M annually) ≈4M Annual Endodontic Focus on Endodontist Market (≈ 5,000 Endos) Underpenetrated core endodontist market primed for continued disruption, < 20% penetrated in U.S. Root Canal Procedures ≈9M Re
Slide 8: Limitations of Conventional RCT
Limitations of Conventional RCT Limitations in Clinical Outcomes Limitations in Clinical Workflow Ineffective Cleaning Lack of Standardized Protocols • Files only touch 35-65% of the surface of the root canal • Lack of standardized protocols for the most • >74% of canals show signs of residual tissu
Slide 9: The Root Canal System is Complex
The Root Canal System is Complex …making them difficult to Root canals are complex… effectively and efficiently clean The Bacteria penetrates the microscopic Problem spaces in the root canal system • Bacteria are smaller than anatomical features in the tooth Unique for each person, root • Canals are
Slide 10: GentleWave System: Proprietary Mechanism of Action
GentleWave System: Proprietary Mechanism of Action 1 Degassing 2 Concentration Adjustments 3 Broad-Spectrum Acoustic Energy 4 Advanced Dynamics Fluid Conventional Root Canal Therapy VS GentleWave Procedure Mechanism of Action Produces Tissue Dissolution Throughout the Root Canal System Confidential
Slide 11: GentleWave System: Proprietary Mechanism of Action
GentleWave System: Proprietary Mechanism of Action
Slide 12: GentleWave Procedure Enables Superior Cleaning
GentleWave Procedure Enables Superior Cleaning Conventional Root Canal Therapy VS Confidential 12
Slide 13: Clinical and Commercial Validation of GentleWave Procedure
Clinical and Commercial Validation of GentleWave Procedure In-Vivo and In-Vitro in… In Real-World, Clinical Practice… The clinical benefits of the GentleWave System have been 2 Prospective, Multi-Center Clinical Studies ~1.7mm Patients Treated with the GentleWave System demonstrated… 30+ Peer-Review
Slide 14: Strong Clinical Outcomes
Strong Clinical Outcomes PURE Study: Single-Arm, Multi-Center, Prospective, Non-Significant Risk Clinical Study High and Rapid Rates of Healing1 Minimal to No Post-Operative Pain2,3,4,5 GentleWave® Procedure: Conventional RCT: GentleWave® Procedure: Conventional RCT: 97% Success Rate Estimated 68-85
Slide 15: GentleWave G4 System: Optimized Performance, Simplified Workflow
DESIGNED FOR REFINED FOR ENHANCED TO DELIVER OPTIMIZED PERFORMANCE A SIMPLIFIED WORKFLOW AN ELEVATED EXPERIENCE Geared to support future software 1 prime per 6 procedures reduces Intuitive, user-friendly interface and evolving features system preparation time between provides step-by-step guidance p
Slide 16: CleanFlow Procedure Instrument: Driving Procedure Simplicity
CleanFlow Procedure Instrument: Driving Procedure Simplicity Previous Generation No components placed CleanFlow PI Molar PI inside tooth CLEANFLOW PROCEDURE INSTRUMENT Simplified & Intuitive Value for Sonendo Commercial Status • Cleans inside of tooth from outside • Fewer parts and easier to assembl
Slide 17: GentleWave System is Best in Class
GentleWave System is Best in Class Traditional Endo1 Sonendo GentleWave System for Endodontics Low Recurring Revenue Per Case High Recurring Revenue Per Case (~$70) Safe and Efficacious ▪ 1.7M GentleWave cases performed show exceptional outcomes and safety profile ▪ Exceptional safety profile of Gen
Slide 18: Recent Financial Results and Guidance
Recent Financial Results and Guidance
Slide 19: Recent Financial Results and Guidance
Recent Financial Results and Guidance ▪ Second Quarter 2025 Financial Results o Generated $7.4 million of total revenue, an 11% decline compared to the prior year period and which was driven entirely by lower console sales; o Reported an increase in gross margin to 41% for the second quarter of 2025
Slide 20: Gaining Consistent Operating Leverage
Gaining Consistent Operating Leverage See information included in the Company’s Form 8-K filed with the SEC on November 12, 2024 for additional information about the Company’s use of non-GAAP financial measures such as adjusted gross margin, adjusted EBITDA, and free cash flow. For a reconciliation
Slide 21: Levers to Accelerate Free Cash Flow Generation
Levers to Accelerate Free Cash Flow Generation ▪ Opportunity to exceed 9% 5-year revenue CAGR (2024-2029) o Drive higher consumable sales through various commercial programs o Drive higher capital sales by more aggressively upgrading 3 rd Gen GentleWave consoles to G4 o Execute business development
Slide 22: Thank You
Thank You N . onendo
Slide 23: Appendix A: Historical Financial Information
Appendix A Historical Financial Information
Slide 24: Historical Financial Results - Reconciliation of GAAP to Non-GAAP
Historical Financial Results - Reconciliation of GAAP to Non-GAAP $ in 000's, unless otherwise noted Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 FY 2023 FY 2024 Revenue $ 8,678 $ 8,763 $ 8,163 $ 9,024 7,047 8,314 8,036 $ 8,305 $ 7,366 $ 7,391 $ 34,628 $ 31,702 Gro